GlassScriptPhysician profile
Paula Jean Rookis
NPI 1962467969
$5,631.80
in general payments reported to CMS, 2019-2025
30 companies · $563 in 2025
The $563 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,250 · 2020: $802 · 2021: $955 · 2022: $717 · 2023: $847 · 2024: $498 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,843 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,843.22 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $885.66 | 2022-2025 | Botox |
| Medtronic USA, INC. | $689.71 | 2019-2020 | |
| Allergan, INC. | $680.64 | 2019-2022 | |
| Astellas Pharma US INC | $660.42 | 2019-2025 | Veozah, Myrbetriq |
| Coloplast Corp | $360.36 | 2019-2023 | Saffron |
| Medtronic, INC. | $328.96 | 2021-2024 | Interstim |
| Sumitomo Pharma America, INC. | $305.90 | 2023-2025 | Gemtesa |
| Boston Scientific Corporation | $304.04 | 2019-2025 | Lynx System, Bulkamid - Bulkamid Urethral Bulking Pack 2ml (Ous), Advantage System |
| Axonics, INC. | $167.72 | 2020-2023 | Axonics |
| Urovant Sciences INC | $159.73 | 2021-2022 | |
| Rochester Medical Corporation | $141.91 | 2021 | |
| Endo Pharmaceuticals INC. | $126.22 | 2022-2024 | Xiaflex, Aveed |
| Caldera Medical, INC | $125.70 | 2021-2022 | |
| Therapeuticsmd, INC. | $118.68 | 2019-2021 | |
| Tolmar, INC. | $100.64 | 2023-2025 | Jatenzo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $85.58 | 2024-2025 | Xyosted, Tlando |
| Ferring Pharmaceuticals INC. | $70.74 | 2019-2020 | |
| Convatec INC. | $63.66 | 2019-2020 | |
| Pfizer INC. | $41.13 | 2019-2022 | |
| Baxter Healthcare | $36.72 | 2022 | |
| Verity Pharmaceuticals INC. | $30.91 | 2024 | Trelstar |
| Endo USA, INC. | $23.10 | 2024 | Xiaflex |
| Blue Earth Diagnostics | $20.16 | 2023 | |
| Amgen INC. | $19.67 | 2025 | Uplizna |
| Conmed Corporation | $18.17 | 2022 | |
| Mission Pharmacal Company | $17.86 | 2019 | |
| Hollister Incorporated | $15.16 | 2023 | Infyna Chic, Onli |
| Allegis Pharmaceuticals, LLC | $12.74 | 2023 | Urimar-T Caps |
| Duchesnay USA Incorporated | $12.27 | 2019 | |
| Travere Therapeutics, INC. | $7.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Rookis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.